Liraglutide
Liraglutide (Saxenda / Victoza)
GLP-1 Receptor Agonist for Weight Loss
What is Liraglutide?
Liraglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. The engineered compound shares 97% amino acid sequence homology with endogenous GLP-1 but incorporates a C16 fatty acid side chain attached via a glutamate linker. This structural modification allows liraglutide to bind to plasma albumin, dramatically extending its half-life from approximately 2 minutes for native GLP-1 to approximately 13 hours for liraglutide, enabling once-daily subcutaneous dosing.
Liraglutide exerts its effects by binding to and activating the GLP-1 receptor, a G protein-coupled receptor found on pancreatic beta cells, in multiple regions of the brain, in the gastrointestinal tract, and in the cardiovascular system. At the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion and suppresses glucagon release, producing glycemic control without hypoglycemia in the fasting state. In the brain, particularly in hypothalamic and brainstem regions governing appetite and energy homeostasis, GLP-1 receptor activation reduces appetite and increases satiety. Research has confirmed that weight loss with liraglutide is driven primarily by reduced energy intake rather than by increased energy expenditure.
The SCALE clinical program, a series of phase III randomized controlled trials, established liraglutide 3.0 mg daily (marketed as Saxenda for obesity) as an effective anti-obesity pharmacotherapy. In the landmark SCALE Obesity and Prediabetes trial published in the New England Journal of Medicine, participants receiving liraglutide 3.0 mg lost an average of 8.4 kg (approximately 8% of body weight) over 56 weeks, compared to 2.8 kg in the placebo group. More than 60% of liraglutide-treated participants achieved at least 5% weight loss. Additional SCALE trials demonstrated benefits in glycemic outcomes, cardiovascular risk markers, and weight maintenance after prior lifestyle intervention.
Liraglutide was FDA-approved as Victoza (1.2 mg and 1.8 mg) for type 2 diabetes mellitus in 2010 and as Saxenda (3.0 mg) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity in 2014. These are among the most firmly established regulatory approvals for any peptide compound currently available.
Research Supply
Source high-purity Liraglutide for your research
Dosage Guide
Route: Subcutaneous injection, once daily (any time, with or without food)
Dosing Schedule
| Period | Dose |
|---|---|
| Week 1 | 0.6 mg daily (tolerability titration) |
| Week 2 | 1.2 mg daily (intermediate titration) |
| Week 3 | 1.8 mg daily (intermediate titration) |
| Week 4 | 2.4 mg daily (near-maintenance) |
| Week 5 onward | 3.0 mg daily (full therapeutic dose for weight loss) |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 0.6 mg | 0.10 mL | Pen dial to 0.6 mg mark |
| 1.8 mg | 0.30 mL | Pen dial to 1.8 mg mark |
| 3.0 mg | 0.50 mL | Pen dial to 3.0 mg mark (maximum approved dose) |
Cycling Protocol
Indefinite (chronic weight management)
Discontinue if 5% weight loss is not achieved after 12 weeks at 3.0 mg
Liraglutide is indicated for chronic use; weight regain typically occurs after discontinuation
Administration Tips
- A gradual dose escalation is mandatory to minimize gastrointestinal side effects, particularly nausea
- For type 2 diabetes management, the approved maintenance doses are 1.2 mg or 1.8 mg daily
- For weight management (Saxenda), the target dose is 3.0 mg daily
- If a patient cannot tolerate at least 1.2 mg after the escalation period, discontinuation is recommended
- Preferred injection sites: abdomen, thigh, or upper arm; do not inject into areas of lipodystrophy
- Rotate injection sites with each injection
Risks & Side Effects
Commonly Reported
Serious Risks
Pancreatitis
Cases of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, have been reported. Liraglutide should be discontinued immediately if pancreatitis is suspected.
Thyroid C-cell tumors
Liraglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors in animal studies. Liraglutide carries a black box warning for this risk and is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
Gallbladder disease
Rapid weight loss from any cause increases gallstone risk; liraglutide-related weight loss is no exception.
Renal impairment
Acute kidney injury and worsening of pre-existing renal disease have been reported, often in the setting of severe dehydration from vomiting or diarrhea.
Hypoglycemia
Most likely when combined with insulin or sulfonylureas; not common with liraglutide monotherapy.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to liraglutide
- Pregnancy (weight loss is not recommended during pregnancy; limited human safety data)
- Type 1 diabetes or diabetic ketoacidosis (not indicated)
- History of pancreatitis (use with caution or avoid)
Frequently Asked Questions
Related Peptides
Experts Covering Liraglutide
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Liraglutide is FDA-approved under specific brand names for specific indications; use outside those approved indications may be off-label. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.